- New-Home Sales Jump to Highest Level in Over Year
- Consumer Mood Improves, but Anxiety Over Finances
- Airlines Hit With Penalties for Stranding Passengers
- Jobless Claims Below 500,000, Durable Orders Slip
- US Said It Will Reduce Emissions by 17% by 2020
- Garlic Price Rises Surpass Gold, Stocks in China
- Judge Erases Couple's $525,000 Mortgage Payment
- Black Friday: Can Banks Tap the Frenzy, Too?
- Blue Jeans Expected to See Another Green Christmas
- 4 Food Stocks to Stuff in Your Portfolio: Analyst
- S&P at 1050-1200 Trading Range Next Year: Strategist
- Treasury On Mortgage Modifications
- Blue Jeans Expected to See Another Green Christmas
- Investors Thankful for Gains This Year
- Thanksgiving & the Markets
- Art Cashin: Caution 'Growing' in Financials, Dividend Moves
- Topless Business Is Taking Off
- 3 Software Stock Picks from Lazard's Senior Analyst
MOST SHARED
- Ritz-Carlton ?Struggling? in the US: President
- Garlic Price Rises Surpass Gold, Stocks in China
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Half of Banks' Losses May Still Be Hidden: IMF Head
- New-Home Sales Jump 6.2% To Highest Level in Over Year
- Oil Price to Average $75.40 in 2010: Poll
- Obama Reiterates Commitment to Boost US-India Ties
- Consumer Mood Improves, But Anxiety Over Personal Finances
- Jobless Claims Below 500,000, Durable Orders Slip
Text Size 
Roche's $43.7 billion offer to buy Genentech may not be the last one, Birgit Kulhoff, pharmaceuticals analyst at Rahn & Bodmer told CNBC Monday.
Swiss-based pharmaceutical company Roche, which already owns 55.9 percent of Genentech [DNA
Loading...
()
], is offering $89 per share to buy up the remaining stake, a 9 percent premium to the biotech company's closing share price on Friday.
"I think for Roche this proposed deal at least at the current terms is positive, for Genentech I think they probably will not be too happy because it really gives rather low valuation to Genentech," Kulhoff told "Worldwide Exchange." "I think we might see higher bids in the end."
A combined entity would have a bigger marketing clout, would cooperate better in research and development and would lower costs, she said.
"In the end it could make sense, but of course that all depends on the price," Kulhoff said.
RELATED LINKS
It will be very important for Roche to maintain the culture of research and development at Genentech and to keep the innovation there going, she added.
Consolidation might continue with pharmaceutical companies buying biotech firms, as the valuations of biotech companies are still reasonable, Kulhoff said.
"That could be the start of a bigger M&A wave," she added.
Print
Email
- Here's how key provisions of the health care reform bill would impact your insurance and how you'll pay for it.
- Playboy will outsource its publishing operations in a bid to become profitable again.
- Remember when auto shows were major events where new models could generate buzz?
- After nine years the NBA’s minor league equivalent is finally coming into its own.
- Bill Griffeth is taking a leave of absence from CNBC and Power Lunch for a year. Here's a message from Bill.
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
Data is a real-time snapshot *Data is delayed at least 15 minutes